ReviewExpert review of vaccines2010
Gene-expression profiling in vaccine therapy and immunotherapy for cancer.
Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 76 citations in OpenAlex.
- Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer.Journal for immunotherapy of cancer · 2025Trial
- Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.Cancer immunology, immunotherapy : CII · 2016Trial
- Trial
- Arboviruses in Cancer therapy: pros and cons.Journal of neurovirology · 2026Review
- Identification of key biomarkers and potential therapeutic drugs in nasopharyngeal carcinoma based on comprehensive bioinformatics analysis.Discover oncology · 2025Article
- Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury.Cancer immunology, immunotherapy : CII · 2025Observational
- The immune landscape of solid pediatric tumors.Journal of experimental & clinical cancer research : CR · 2022Article
- Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.Clinical and translational medicine · 2021Article
- Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis.Molecular and cellular biochemistry · 2021Article
- The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy.Emerging topics in life sciences · 2017Article
- Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells.Nature communications · 2017Article
- Article
- Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.Annals of translational medicine · 2017Review
- Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.Scientific reports · 2016Article
- Checkpoint Inhibitors and Their Application in Breast Cancer.Breast care (Basel, Switzerland) · 2016Review
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.Journal for immunotherapy of cancer · 2016Review
- Review
- Overcoming tumor immune evasion with an unique arbovirus.Journal of translational medicine · 2015Review
- Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.The international journal of biochemistry & cell biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
The identification of tumor antigens recognized by T cells led to the design of therapeutic strategies aimed at eliciting adaptive immune responses. The last decade of experience has shown that, although active immunization can induce enhancement of anticancer T-cell precursors (easily detectable in standard assays), most often they are unable to induce tumor regression and, consequently, have scarcely any impact on overall survival. Moreover, in the few occasions when tumor rejection occurs, the mechanisms determining this phenomenon remain poorly understood, and data derived from in vivo human observations are rare. The advent of high-throughput gene-expression analysis (microarrays) has cast new light on unrecognized mechanisms that are now deemed to be central for the development of efficient immune-mediated tumor rejection. The aim of this article is to review the data on the molecular signature associated with this process. We believe that the description of how the mechanism of immune-mediated tissue destruction occurs would contribute to our understanding of why it happens, thereby allowing us to develop more effective immune therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.